ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Regeneron PharmaceuticalsAlnylam Pharmaceuticals
studies on the registry41384
open to participants now8318
phase 3 studies under way385
reach primary completion within a year308
programswith a study of their own in two years4311

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseRegeneron PharmaceuticalsAlnylam Pharmaceuticals
Phase 1

Regeneron Pharmaceuticals: 8 of its 43 programs at phase 1

  1. REGN9533phase 1
  2. ALN-SNCAphase 1
  3. REGN17235phase 1
  4. REGN20423phase 1
  5. REGN20934phase 1

and 3 more — sign in to see them all

19%

Alnylam Pharmaceuticals: 4 of its 11 programs at phase 1

  1. ALN-4285phase 1
  2. ALN-4915phase 1
  3. ALN-5288phase 1
  4. ALN-6222phase 1
36%
Phase 2

Regeneron Pharmaceuticals: 16 of its 43 programs at phase 2

  1. ALN-PNPphase 2
  2. vonsetamigphase 2
  3. ALN-ANG3phase 2
  4. olsutamigphase 2
  5. ubamatamabphase 2

and 11 more — sign in to see them all

37%

Alnylam Pharmaceuticals: 5 of its 11 programs at phase 2

  1. mivelsiranphase 2
  2. ALN-4324phase 2
  3. ALN-6400phase 2
  4. ALN-AGT01 RVRphase 2
  5. ALN-2232phase 2
45%
Phase 3

Regeneron Pharmaceuticals: 15 of its 43 programs at phase 3

  1. cemiplimabphase 3
  2. cenvacibartphase 3
  3. fianlimabphase 3
  4. odronextamabphase 3
  5. amrecibartphase 3

and 10 more — sign in to see them all

35%

Alnylam Pharmaceuticals: 2 of its 11 programs at phase 3

  1. nucresiranphase 3
  2. zilebesiranphase 3
18%
Approved, new studies

Regeneron Pharmaceuticals: 4 of its 43 programs at approved, new studies

  1. linvoseltamabapproved, new study
  2. pozelimabapproved, new study
  3. dupilumabapproved, new study
  4. alirocumabapproved, new study
9%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Regeneron Pharmaceuticals14 readouts · 4 phase 3·

Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion

  1. ALN-ANG3phase 2 · Dec 4 · NCT06452771
  2. alirocumabapproved, new study · Dec 29 · NCT07477704

Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fianlimabphase 3 · Jan 15 · NCT05608291

Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion

  1. REGN22044phase 1 · Feb 8 · NCT07526116
  2. amrecibartphase 3 · Feb 9 · NCT07175428
  3. cenvacibartphase 3 · Feb 9 · NCT07175428
  4. REGN20934phase 1 · Feb 22 · NCT07594093

Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cemiplimabphase 3 · Mar 22 · NCT06246916

Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. REGN9533phase 1 · Apr 2 · NCT07759167
  2. dupilumabapproved, new study · Apr 24 · NCT06572228
·

Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mibavademabphase 3 · Jun 18 · NCT07220772
·

Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion

  1. ALN-PNPphase 2 · Aug 10 · NCT05648214
  2. ALN-CIDEBphase 3 · Aug 17 · NCT06836609
  3. linvoseltamabapproved, new study · Aug 31 · NCT06369467
··
Alnylam Pharmaceuticals6 readouts · 0 phase 3·

Alnylam Pharmaceuticals, Dec ’26: 1 program whose next study reaches primary completion

  1. ALN-4285phase 1 · Dec 29 · NCT07295717
···

Alnylam Pharmaceuticals, Apr ’27: 1 program whose next study reaches primary completion

  1. ALN-2232phase 2 · Apr 28 · NCT07463846

Alnylam Pharmaceuticals, May ’27: 1 program whose next study reaches primary completion

  1. ALN-4324phase 2 · May 28 · NCT07465224

Alnylam Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. ALN-6400phase 2 · Jun 30 · NCT07575308

Alnylam Pharmaceuticals, Jul ’27: 1 program whose next study reaches primary completion

  1. ALN-4915phase 1 · Jul 31 · NCT07535606

Alnylam Pharmaceuticals, Aug ’27: 1 program whose next study reaches primary completion

  1. mivelsiranphase 2 · Aug 9 · NCT06393712
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Regeneron Pharmaceuticals

New programs 5

  • REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
  • REGN13089phase 2 · first study · Oct 2 · Carcinoma, Renal Cell
  • REGN24493phase 1 · first study · Sep 30 · Graves Disease
  • REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
  • ALN-6457phase 2 · first study · Sep 16 · Dementia

Reached a new phase 2

Study stopped 0

None

Primary completion later 6

Alnylam Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 3 in all. A program counts in each condition its studies name most.

ConditionRegeneron PharmaceuticalsAlnylam Pharmaceuticals
Obesityboth · compare here

Regeneron Pharmaceuticals in Obesity: 5 programs

  1. ALN-CIDEBphase 3
  2. olatorepatidephase 3
  3. mibavademabphase 3
  4. garetosmabphase 3
  5. REGN20934phase 1

Their studies: Regeneron Pharmaceuticals’ studies of Obesity in search

Alnylam Pharmaceuticals in Obesity: 3 programs

  1. ALN-4324phase 2
  2. ALN-2232phase 2
  3. ALN-6222phase 1

Their studies: Alnylam Pharmaceuticals’ studies of Obesity in search

Hypertensionboth · compare here

Regeneron Pharmaceuticals in Hypertension: 1 program

  1. vixticibartphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Hypertension in search

Alnylam Pharmaceuticals in Hypertension: 2 programs

  1. zilebesiranphase 3
  2. ALN-AGT01 RVRphase 2

Their studies: Alnylam Pharmaceuticals’ studies of Hypertension in search

Diabetes Mellitus, Type 2both · compare here

Regeneron Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Regeneron Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Alnylam Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program

  1. ALN-4324phase 2

Their studies: Alnylam Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Regeneron Pharmaceuticals 17 of 43 · Alnylam Pharmaceuticals 0 of 11 programs (16 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.